MagicMed

MagicMoments Podcast

MagicMoments, a new series focused on providing insights into a wide range of topics in the psychedelic, biotechnology and pharmaceutical industries.

FAQ

A class of psychoactive/chemical substances that produce changes in perception, mood, and cognitive presence.

  • Magic Mushrooms -Psilocybin and psilocin
  • MDMA – 3,4-Methyl​enedioxy​methamphetamine 
  • LSD – Lysergic acid diethylamide 
  • DMT – N,N-dimethyltryptamine 
  • Ibogaine
  • Mescaline – 3,4,5-trimethoxyphenethylamine

Psychedelics have shown the potential to provide improved, alternative treatments or solutions to a vast array of brain and mental health indications such as – treatment-resistant depression, anxiety, post-traumatic stress disorder (PTSD), cluster headaches / migraines, and substance abuse disorders.

Derivatives are a collection of molecules that share a common chemical structure with a particular psychedelic molecule. Each derivative has a chemical difference that could have a pronounced effect on the human body.

To develop a psychedelic derivative, MagicMed starts by synthesizing novel molecules and testing them to determine their pharmacological properties. These compounds are added to the Psybrary™  where partners can select them based on their pharmacological profile. After early research and development MagicMed’s partners will select particular molecules from the proprietary Psybrary™ and advance them through clinical trials as required by regulatory agencies. Marketing approval will be required from the health regulators, such as Health Canada, FDA, or EMA, before the medicinal products can be sold.

Pharmaceutical, biotechnology corporations, leading wellness-focused psychedelics companies, and wellness-focused cannabis producers entering the psychedelic space.

Derivative molecules have improved product effectiveness and reduce toxicity for patients while potentially lowering manufacturing costs, expediting the development process, and are patentable.

Synthetic biology is a field of science that repurposes existing genes and proteins in (from) nature to engineer something new.

The Artificial Intelligence technology that MagicMed is developing, called PsyAI™, is a tool designed to streamline pharmaceutical design by predicting structure, manufacturing capabilities and pharmacological effects in an effort to accelerate the modernization of psychedelic medicines. Combining PsyAI™ and the Psybrary™, MagicMed’s large-scale novel molecule creation platform, creates an opportunity to accelerate the development of optimized pharmaceutical candidates, each tailored specifically for difficult-to-treat mental health indications. 

The Artificial Intelligence technology that MagicMed is developing, called PsyAI™, is a methodology that will accomplish two key deliverables: i) narrow down the library of millions of pharmaceutical candidates to a testable number; and ii) expedite the drug development process. This approach is modeled to streamline the pharmaceutical design by predicting what a good potential drug candidate could be and what a good structure should look like. As a result, the pharmacological effects and manufacturing efforts to accelerate the modernization of psychedelic medicines would be optimized.

The birth of MagicMed occurred as a response to the huge global need for Mental and Behavioral Health solutions. Decades of unmet, under serviced, and under appreciated medical experiences has led to a vast array of mental challenges in society today. In addition, since the creation of selective serotonin reuptake inhibitors (SSRIs), 40 years ago, there has been limited innovation in the space. 

Why our position?
Statistically, the UN tells us that people with “mental and psychosocial disabilities represent a significant proportion” of our global population. In any given year, 1 in 5 Canadians will experience a mental health episode or illness according to the Centre for Addiction and Mental Health (CAMH). Furthermore, only about 50% of Canadians experiencing a major depressive episode receive adequate care. Lastly, 1 in 5 American adults are living with a vast range of mental illness conditions and severities. (NIH)

The Psybrary is a unique resource in the psychedelic space because of the techniques used to create it, its scale and the company’s use of artificial intelligence.

By combining synthetic biology and chemistry MagicMed is able to synthesize more chemical novelty than competitors. To speed up the screening of the large number of drug candidates, MagicMed utilizes a unique AI approach known as PsiAI. PsiAI helps MagicMed discover which of the many compounds it can synthesize will be the most valuable to its partners and their patients.

Reference: